CN112603940A

CN112603940A - Preparation and application of active extract of gout decoction powder for resisting hyperuricemia and gout diseases

Info

Publication number: CN112603940A
Application number: CN202110145819.7A
Authority: CN
Inventors: 陈海芳; 张武岗; 冯育林; 杨世林; 杨武亮; 郎一帆; 安琼; 李国峰
Original assignee: Jiangxi University of Traditional Chinese Medicine
Current assignee: Jiangxi University of Traditional Chinese Medicine
Priority date: 2021-02-03
Filing date: 2021-02-03
Publication date: 2021-04-06

Abstract

The invention provides a preparation method of an active extract of gout decoction powder for resisting hyperuricemia and gout diseases. The active extract obtained by the invention contains polyphenols, flavonoids and alkaloids substances, wherein the UV content of total polyphenols is more than 50%, the UV content of total flavonoids is more than 4%, and the UV content of total alkaloids is more than 0.4%. In addition, the active extract has the functions of obviously inhibiting the activity of xanthine oxidase, reducing the levels of serum uric acid, urea nitrogen, creatinine, IL-6 and IL-1 beta and inhibiting the joint swelling of gouty arthritis, and can be developed into a novel medicine for treating hyperuricemia and gout diseases independently or in combination with other medicines.

Description

Preparation and application of active extract of gout decoction powder for resisting hyperuricemia and gout diseases

Technical Field

The invention belongs to the field of traditional Chinese medicines, and relates to preparation and application of an active extract of gout decoction powder for resisting hyperuricemia and gout diseases.

Background

In vivo purine metabolic disorder can increase uric acid production, leading to abnormal increase of uric acid level in vivo, and causing Hyperuricemia (HUA). Long-term HUA can cause urate crystals (MSU) to deposit on tissues such as joints or subcutaneous tissues to cause inflammatory diseases, and finally gout develops. Clinically, the joint pain is characterized by repeated attack of red, swelling, heat and pain and limited joint movement, and can cause the joint movement of patients to generate disorder and skeletal deformity in later period.

According to statistics, the incidence rate of global gout is generally 1-4%, the incidence rate of western countries reaches about 10%, and the incidence rate of national countries is 1-3%, and the incidence rate of global gout is on the trend of increasing year by year. Meanwhile, gout which is called as 'rich disease' from ancient times is a risk factor of various diseases such as diabetes, chronic kidney disease, obesity, hypertension, kidney stone, myocardial infarction, heart failure, stroke and the like; national health and nutrition survey (NHANES) data show: of the gout patients, 69.1% had hypertension, 62.9% had obesity, 33.1% had type 2 diabetes, 53.7% had hyperlipidemia, 47.4 had hypercholesterolemia, 24% had stage 3 chronic kidney disease, and 7.4% had atrial fibrillation. The long-term increase of the risk of hypertension, diabetes, cardiovascular diseases and urinary calculus complications caused by the blood uric acid level higher than 360 mu mol/L is found in the follow-up visit of a large number of gout patients all year round; more than 50% of patients who die from gout have cardiovascular disease, and the mortality rate due to cardiovascular disease is positively correlated with the severity of gout.

At present, the clinical treatment of hyperuricemia and gout diseases at home and abroad adopts a scheme of reducing serum uric acid, diminishing inflammation and relieving pain, and the medicaments mainly comprise allopurin, benzbromarone, febuxostat, colchicine and the like. Although the medicines can effectively relieve clinical symptoms of patients, the chronic gout patients can have serious side effects of allergy, liver injury, immunogenicity and the like after long-term administration.

Gout diseases are a typical disease species of the Tibet plateau, and Tibetan medicine forms some classical prescriptions in the long-term treatment process of the diseases. Wherein the gout decoction powder is collected in Tibetan medicine Standard, is prepared by mixing coarse powders of 3 raw medicinal materials of myrobalan, le hucho and sediment Xun paste, has the effects of diminishing inflammation and relieving pain and is used for treating gout, lower limb joint swelling and pain and the like. However, no report has been made on the active ingredients of gout powder decoction for resisting hyperuricemia and gout diseases and the preparation thereof.

The gout powder decoction recorded in Tibetan medicine standards is directly orally taken by crude drug powder, the taking mode reduces the bioavailability of active ingredients of the gout powder decoction, increases the daily dose of the gout powder decoction, and the pharmaceutical ingredients are not clear so far, so that the gout powder decoction is limited to be clinically applied to a certain extent.

Disclosure of Invention

Aiming at the problems that the gout powder is used as raw powder, the active ingredients are not clear, the daily dose is large and the like, the invention adopts a pharmacological activity tracking method to evaluate the drug effects of different extracts of the gout powder on the hyperuricemia and gout diseases, determines the active extracts of the gout powder on the hyperuricemia and the gout, analyzes the components of the active extracts, and determines the chemical composition of the gout powder. Finally, the preparation method of the gout resisting decoction powder anti-hyperuricemia and gout active extract with definite chemical components, controllable quality and guaranteed drug effect is established.

The active extract of the invention is mainly composed of polyphenols, alkaloids and flavonoids, wherein the UV content of total polyphenols is more than 50%, the UV content of total flavonoids is more than 4%, and the UV content of total alkaloids is more than 0.4%.

The active extract is prepared by the following steps:

a) mixing medicine materials of myrobalan, hucho and sediment Xun paste according to the mass ratio of 5:4:2, heating and refluxing the medicine materials for 2-4 times by using 60-90% ethanol water in an amount which is 5-20 times (mass/volume) of the medicine materials, extracting the medicine materials for 1-3 hours each time, filtering the medicine materials, and combining the medicine materials to obtain an extracting solution A;

b) concentrating the extracting solution A at 40-60 ℃ under reduced pressure until the relative density is 1.01-1.07 (60-70 ℃), and drying in vacuum to obtain a gout powder alcohol extract B;

c) and dissolving the alcohol extract B with 6-12 times (g/mL) of water, adsorbing by 10-20 times (g/mL) of macroporous resin, sequentially carrying out gradient elution by using ethanol water solutions with different volume concentrations, collecting 50-70% ethanol water eluent, merging, and carrying out vacuum drying to obtain the gout powder active extract.

The macroporous absorption resin is selected from AB-8, HPD-400, D101, NKA-9 and HPD-826.

The invention also relates to a pharmaceutical composition, which comprises the gout powder active extract and pharmaceutically acceptable auxiliary materials.

Further, the pharmaceutical composition is in the form of tablets, capsules, granules, powder, pills, extracts, oral liquid or syrups.

The invention also relates to application of the active extract of the gout decoction powder in preparing medicines for resisting hyperuricemia and gout. In particular to the application in preparing anti-gout drugs.

Aiming at the problems of complex raw powder, undefined main active ingredients, large daily dose and the like of the gout powder, the preparation process of the gout powder active extract adopts an active guided fractionation method, avoids the loss of target ingredients, obviously improves the content of the active ingredients, and has the advantages of more definite main active ingredients and high extraction rate. The concrete points are as follows: the gout powder active extract mainly comprises polyphenol, flavone and alkaloid components, and the ultraviolet spectrophotometer detects that the content of total polyphenol in the active extract is more than 50%, the content of total flavone is more than 4%, and the content of total alkaloid is more than 0.4%.

The gout powder active extract has the medicinal effects of resisting hyperuricemia and resisting gout. Particularly shows that the compound can obviously inhibit the activity of xanthine oxidase, reduce the levels of serum uric acid, urea nitrogen, creatinine, IL-6 and IL-1 beta and has obvious inhibiting effect on joint swelling of gouty arthritis.

Therefore, the gout powder active extract has obvious advantages in the aspects of medicinal material utilization rate, clear main medicinal effect components, reduction of daily dose, improvement of curative effect and the like. The compound can be further developed into anti-hyperuricemia and anti-gout drugs, and has wide market prospect.

Drawings

FIG. 1 is a wavelength scan of total polyphenols;

FIG. 2 is a standard curve for total polyphenol content determination;

FIG. 3 is a wavelength scan of total flavonoids;

FIG. 4 is a standard curve of total flavone content measurement;

FIG. 5 is a wavelength scan of total alkaloids;

FIG. 6 is a standard curve for total alkaloid content determination.

Detailed Description

The technical solutions in the embodiments of the present invention will be clearly and completely described below, and it is obvious that the described embodiments are only a part of the embodiments of the present invention, and not all embodiments. All other embodiments, which can be derived by a person skilled in the art from the embodiments given herein without making any creative effort, shall fall within the protection scope of the present invention.

Identification of chemical component species in active extract

Water-soluble ingredients: taking 10g of active extract, adding 50ml of distilled water, soaking in 50-60 deg.C water bath for 2 hr, filtering, and collecting filtrate.

Alcohol-soluble ingredients: extracting active extract 10g with ethanol 100ml under reflux in boiling water bath for 1 hr, and filtering. Recovering ethanol from the filtrate, and concentrating until no alcohol smell is generated. The results are shown in Table 1.

As is clear from the results in table 1, the active extract of gout powder mainly contains polyphenols (phenols and tannins), flavones, alkaloids and saccharides.

Method for measuring content of main chemical components in active extract

2.1 Total Polyphenol assay

Preparing a reference substance solution: weighing appropriate amount of gallic acid reference substance, placing in 10mL volumetric flask, dissolving with methanol and fixing volume to scale mark, shaking, diluting to 100 μ g/mL to obtain reference substance solution, and storing in 4 deg.C refrigerator for use.

Preparing a sample solution: weighing 2.04mg of gout decoction powder 60% ethanol water eluate, placing in a 10mL volumetric flask, dissolving with methanol, fixing the volume to the scale mark, shaking to obtain a sample solution, and storing in a refrigerator at 4 deg.C for later use.

Wavelength selection: accurately sucking 1mL of each of the reference solution and the sample solution, placing into 25mL volumetric flasks, adding 1mL of Folin phenol reagent, reacting for 3min in dark place, adding 1.5mL of 15% Na₂CO₃The solution is added with water to a constant volume to be calibrated, and is subjected to water bath at 50 ℃ for 60min, and the corresponding solution is used as a reference solution. Full-wavelength spectrum scanning is carried out at 400-900 nm, and the result shows that the absorption maximum exists at 755nm (see figure 1).

The standard curve is prepared by placing reference solution 0.25 mL, 0.5 mL, 0.75 mL, 1mL, 1.25 mL, 1.5mL, and 1.75mL into test tube, adding Folin phenol reagent 1mL, reacting for 3min in dark place, adding 2mL15% Na2CO3 solution, adding water to constant volume to scale, and water bathing at 50 deg.C for 60 min. Absorbance (A value) was measured at 755nm wavelength with control concentration C (μ g/mL) as abscissa and absorbance (A value) as ordinate, resulting in standard regression equation y = 0.0493x + 0.0722 (R)²= 0.9991), indicating that gallic acid is in a good linear relationship with absorbance in the range of 1-7 ug/mL (see fig. 2).

Determination of total flavone content

Preparing a reference substance solution: precisely weighing 25.0mg of rutin reference substance, placing in a 50mL brown volumetric flask, dissolving with 60% ethanol, and metering to the scale mark to obtain 500 ug/mL rutin reference substance solution, and storing in a refrigerator at 4 deg.C for use.

Preparing a sample solution: weighing 10 mg of gout decoction 60% ethanol water eluate, placing in a 10mL volumetric flask, dissolving with methanol, metering to a scale mark, shaking to obtain a sample solution, and storing in a refrigerator at 4 deg.C for use.

Wavelength selection: accurately sucking 1mL of each of the control solution and the sample solution, placing into 9 test tubes with plugs, respectively, adding 5% NaNO₂0.3mL of the solution was shaken up, left to stand for 6min, and 10% Al (NO) was added₃)₃0.3mL of solution, shaking up, standing for 6min, adding 5mL of 4% NaOH solution, mixing uniformly, fixing the volume to 10mL by using 60% ethanol, standing for 20min, taking a corresponding reagent as a blank, and performing full-wavelength spectrum scanning at 400-800 nm, wherein the maximum absorption is at 510nm, so that the measurement wavelength of 510nm is selected (see figure 3).

The preparation of the standard curve comprises transferring the above prepared solutions 0.1, 0.2, 0.4, 0.6, 0.8 and 1.0 into 10mL colorimetric tubes with plugs, and adding 5% NaNO₂0.3mL of the solution was shaken up, left to stand for 6min, and 10% Al (NO) was added₃)₃0.3mL of solution, shaking uniformly, standing for 6min, adding 5mL of 4% NaOH solution, mixing uniformly, fixing the volume to 10mL by using 60% ethanol, standing for 20min, measuring the absorbance (A value) at the wavelength of 510nm, taking the rutin concentration C (ug/mL) as the abscissa and the absorbance (A value) as the ordinate, and obtaining a standard regression equation y =0.0057x-0.0015 (R)²= 0.9992), indicating that rutin is in a range of 5-50 ug/ml and has a good linear relation with absorbance (see figure 4).

Total alkaloid content determination

Preparing a reference substance solution: weighing 1.69mg of berberine hydrochloride reference substance, placing in a 10mL volumetric flask, dissolving with methanol, metering volume to scale mark, shaking to obtain reference substance solution, and storing in a refrigerator at 4 deg.C for use.

Preparing a sample solution: weighing 100mg of gout decoction powder 60% ethanol water eluate, placing in a 10mL volumetric flask, dissolving with methanol, fixing the volume to a scale mark, shaking up to obtain a sample solution, and storing in a refrigerator at 4 ℃ for later use.

Wavelength selection: accurately sucking 1mL of each of a reference solution and a test solution, placing the reference solution and the test solution into conical flasks with stoppers respectively, volatilizing the solvent, adding 6mL of an acid dye solution and 6mL of chloroform, shaking uniformly, placing the mixture into a separating funnel, standing for 2 hours, separating a chloroform layer solution, taking a corresponding reagent as a blank, carrying out full-wavelength spectrum scanning at 400-800 nm, and selecting a measurement wavelength of 415nm (see figure 5) as a result, wherein the maximum absorption is at 415 nm.

Preparation of a standard curve: precisely sucking 0.1, 0.2, 0.4, 0.8 and 1.0mL of reference solution into a conical flask, volatilizing solvent, adding 6mL of acid dye solution and 6mL of chloroform, mixing, standing in a separating funnel for 2h, separating chloroform layer solution, measuring absorbance (A value) at a wavelength of 415nm, taking the concentration C (ug/mL) of the reference as abscissa and absorbance (A value) as ordinate, and obtaining a standard regression equation y = 0.0733x + 0.0169 (R)²= 0.9994), indicating that berberine hydrochloride has a good linear relationship with absorbance in the range of 1.41-14.1 ug/mL (see fig. 6).

Example 1

The embodiment provides a preparation method of an active extract of gout decoction powder for resisting hyperuricemia and gout diseases, 1000g of a medicine material mixed by myrobalan, hucho and sediment Xun paste is taken according to the mass ratio of 5:4:2, 10 times of 80% ethanol solution is used for heating reflux extraction for 2 times at 75 ℃, 1 hour is used for each time, filtration is carried out, an extracting solution A is obtained by combination, the extracting solution A is concentrated under reduced pressure at 60 ℃ until the relative density is 1.07 (60-70 ℃), and the alcohol extract B137 g of the gout decoction powder is obtained by drying under reduced pressure. Dissolving the alcohol extract B with 10 times of water, adsorbing with 15 times of macroporous adsorption resin AB-8, sequentially eluting with 2 column volumes of water, 30% ethanol water solution, 60% ethanol water solution and 90% ethanol water solution, collecting eluates, and drying under reduced pressure to obtain water eluate 7.7g, 30% ethanol water eluate 39.6 g, 60% ethanol water eluate 30.1g, and 90% ethanol water eluate 2.6 g. Ultraviolet spectrophotometer is used for detecting 52.16% of total polyphenol, 4.61% of total flavone and 0.43% of total alkaloid in 60% ethanol water eluate.

Example 2

Mixing 1000g of medicine materials of myrobalan, hucho and sediment Xun paste according to the mass ratio of 5:4:2, heating and refluxing for 3 times by using 90% ethanol solution of 5 times, extracting for 2 hours each time at 90 ℃, filtering, combining to obtain extracting solution A, concentrating under reduced pressure at 40 ℃ until the relative density is 1.04 (60-70 ℃), and obtaining gout powder alcohol extract B131 g. Dissolving the alcohol extract B with 6 times of water, adsorbing with 10 times of processed macroporous adsorption resin HPD-400, eluting with 2 column volumes of water, 30% ethanol water solution, 60% ethanol water solution and 90% ethanol water solution, respectively, collecting eluates, and drying under reduced pressure to obtain 7.9g water eluate, 35.4g 30% ethanol water eluate, 32.8 g 60% ethanol water eluate and 3.1g 90% ethanol water eluate. Ultraviolet spectrophotometer test shows that the total polyphenol content in 60% ethanol water eluate is 56.6%, total flavone content is 4.14%, and total alkaloid content is 0.51%.

Example 3

Mixing 1000g of medicine materials of myrobalan, hucho and sediment Xun paste according to the mass ratio of 5:4:2, heating and refluxing the medicine materials for 4 times by using 20 times of 60% ethanol solution at the temperature of 60 ℃, filtering the medicine materials, merging the medicine materials to obtain extracting solution A, concentrating the extracting solution A at the temperature of 50 ℃ under reduced pressure until the relative density is 1.01 (60-70 ℃), and obtaining 145g of gout decoction powder alcohol extract B. Dissolving the alcohol extract B with 12 times of water, adsorbing with 20 times of macroporous adsorption resin HPD-826, sequentially eluting with 2 column volumes of water, 30% ethanol water solution, 60% ethanol water solution and 90% ethanol water solution, collecting eluates, and drying under reduced pressure to obtain 8.6g water eluate, 43.5g 30% ethanol water eluate, 31.9 g 60% ethanol water eluate and 2.5g 90% ethanol water eluate. Ultraviolet spectrophotometer is used for detecting the total polyphenol content of 53.74%, total flavone content of 4.22%, and total alkaloid content of 0.46% in 60% ethanol water eluate.

Example 4: experimental method for inhibition of different extracts of gout decoction powder on xanthine oxidase

4.1 preparation of test solutions

Weighing a proper amount of each sample, placing the weighed sample in a 10mL volumetric flask, adding a proper amount of DMSO to promote dissolution, then adding PBS buffer solution to fix the volume to a scale mark, and diluting each sample to 5 different concentrations (see table 2).

4.2 xanthine oxidase inhibitory Activity assay of Each sample

Taking the above samples for later use, wherein the total volume of the reaction system is 200 mu L, sequentially adding 100 mu L of buffer solution, 50 mu L of samples with different concentrations and 50 mu L (0.1U/mL) of enzyme solution to a 96-well plate during reaction, incubating for 3min at 37 ℃ in an enzyme-linked immunosorbent assay, adding 50 mu L (0.48mmol/L) of substrate xanthine to start reaction, and immediately recording an absorbance value (once every 10 s) at 295 nm for 5 min in total. Each concentration was repeated for 3 wells. Calculating the inhibition ratio IC of each sample on xanthine oxidase according to the final concentration of each sample in the reaction system₅₀. The results are shown in Table 3

The inhibition (%) was calculated by the following formula:

inhibition (%) = (Δ ase- Δ a sample)/(Δ ase- Δ a blank) × 100%

Where Δ a refers to the difference in absorbance over time.

As shown in table 3, 30% ethanol water eluate (30X) and 60% ethanol water eluate (60X) obtained after adsorption and desorption of gout decoction alcohol extract (CF) by macroporous resin exhibit significant inhibitory effect on xanthine oxidase. However, IC 60X for xanthine oxidase₅₀30.9. mu.g/mL, is clearly superior to CF (87.57 ug/mL). Therefore, the substances of the alcohol extract of the gout decoction powder for inhibiting the xanthine oxidase activity are mainly concentrated in the 60% ethanol water eluate.

Example 5: inhibition experiment of different extracts of gout powder soup on various biochemical indexes of hyperuricemia model rat

90 male SD rats, freely fed with water and plain feed, were randomized 5 days after acclimation into 9 groups, each: blank group (KB), model group (MX), allopurinol group (BPC, positive control group), fifteen Rupeng pill group (YX2, positive control group), gout decoction alcohol extract group (CF), water eluate group (SX), 30% ethanol water eluate group (30X), 60% ethanol water eluate group (60X), 90% ethanol water eluate group (90X), 10 per group. Except the blank group, the hyperuricemia rat model is constructed by intraperitoneal injection of potassium oxonate in combination with gastric hypoxanthine, after 1h of modeling, 0.5% CMC-Na is given to the blank group and the model group, and the rest groups are given with corresponding drugs for 7 days continuously. Fasting for 12h before the last molding, freely drinking water, administering for 1h, taking blood from orbital venous plexus of rat, standing for 1h at room temperature, centrifuging at 4000r/min for 10min, taking upper layer serum, subpackaging, storing at-30 deg.C, taking liver and kidney, and storing in refrigerator at-30 deg.C for subsequent detection of each index. Serum Uric Acid (SUA), Creatinine (CRE), urea nitrogen (BUN), Xanthine Oxidase (XOD), interleukin 6(IL-6) and interleukin 1 beta (IL-1 beta) levels were measured according to Nanjing's built uric acid kit instructions. The results are shown in tables 4 and 5.

As can be seen from tables 4 and 5, the serum levels of the biochemical indexes in the model group are obviously higher than those in the blank group, and the serum levels of the biochemical indexes in the positive control group of allopurinol and fifteen Rupeng pills are obviously lower than those in the model group, so that the success of modeling of the hyperuricemia model of the test is prompted.

Compared with the model group, the gout powder alcohol extraction group and various biochemical indexes of different alcohol water elution groups of the gout powder alcohol extraction group have lower water average in serum than that of the model group, and particularly, the 60 percent ethanol water elution group has the most obvious effect on various biochemical indexes and is superior to the gout powder alcohol extraction group. Therefore, 60% ethanol water eluate is an anti-hyperuricemia active extract of the gout decoction.

Example 6: experiment for inhibiting arthroncus of gouty arthritis model rats by different extracts of gout decoction powder

90 male SD rats, freely fed with water and plain feed, were randomized 5 days after acclimation into 10 groups, each: blank group (KB), model group (MX), colchicine group (QSX, positive control group), fifteen Rupeng pill group (YX2, positive control group), gout decoction alcohol extract group (CF), water eluate group (SX), 30% ethanol water eluate group (30X), 60% ethanol water eluate group (60X), 90% ethanol water eluate group (90X), 10 per group. Blank, model and positive groups were given 0.5% CMC-Na, the remaining groups were given the corresponding drug for 6 consecutive days. On day 7, each group was given the corresponding drug, and 1h later, molding was started, and the right ankle cavity of the rats in the blank group was injected with 200. mu.l of physiological saline, and the right ankle cavity of the rats in the remaining groups was injected with 200. mu.l of 40mg/mL MSU solution. The volume of the right foot of the rat is measured by a toe swelling measuring instrument before modeling and recorded. The volume of the right foot of each group of rats was measured at 2, 4, 6, 8h, 12h and 24h after the molding, and the toe swelling degree was calculated (see table 6).

Swelling index definition: degree of swelling of joint = (joint circumference-initial circumference at the time of measurement)/initial circumference 100%.

As can be seen from Table 6, the model group rats showed significant swelling in the joints 6h after model creation, peaking at 8h to 12h and spontaneously decreasing at 24h as compared to the normal group. Compared with a model group, the gout decoction powder groups, colchicine and fifteen Rupeng pills have lower joint swelling rates of rats within 6-24 h, particularly the colchicine group (QSX) and the 60% ethanol water eluate group (60X) have obvious inhibition effect on the joint swelling of the rats within 12h, and the 60X group has better inhibition effect on the joint swelling of the rats within 24h than the QSX group. Therefore, 60% ethanol water eluate is an active extract of the gout powder for inhibiting the swelling of the gouty arthritis.

Example 7: preparation of gout decoction powder active extract in different dosage forms

a) The pill is prepared by pulverizing gout powder active extract, starch, and croscarmellose sodium respectively, sieving with 100 mesh sieve, mixing, making into pill with water, drying, and packaging to obtain the final product, wherein each pill contains 0.1-100mg of gout powder active extract.

b) The oral liquid is prepared by dissolving gout powder active extract in water, adding appropriate amount of correctant, adding 5g of active carbon, heating for 30 min, filtering, adding water to 1000ml, filtering, bottling, sterilizing, testing to be qualified, and packaging.

c) The syrup is prepared by dissolving gout powder active extract in water, adding sucrose 500g and antiseptic, boiling for dissolving, filtering, adding water to 1000ml, filtering, bottling, sterilizing, checking, and packaging.

d) Powder, tablet, capsule, granule, and extract are prepared by conventional method, and each tablet or capsule contains 0.1-100mg of gout powder active extract; the powder or granule contains gout powder active extract 0.1-100mg per 1g per pouch, and is packaged after passing inspection.

Finally, it should be noted that the above-mentioned embodiments are only preferred embodiments of the present invention, and not intended to limit the present invention, and although the present invention has been described in detail with reference to the foregoing embodiments, it will be apparent to those skilled in the art that modifications and equivalents can be made in the technical solutions described in the foregoing embodiments, or some technical features thereof can be replaced. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. The gout decoction powder is an active extract for resisting hyperuricemia and gout diseases, and is characterized in that: the active extract comprises polyphenols, flavonoids and alkaloids, and the total polyphenols content, the total flavonoids content and the total alkaloids content in the active extract are respectively detected by an ultraviolet spectrophotometer to be more than 50%, 4% and 0.4%.

2. The method for preparing the active extract of gout powder medicine for resisting hyperuricemia and gout diseases according to claim 1, wherein the extract comprises the following components in percentage by weight: the method comprises the following steps:

a) mixing the medicine materials of myrobalan, hucho and sediment water-conducting paste according to the mass ratio of 5:4:2, heating and refluxing the medicine materials for 2-4 times by using 5-20 times of 60-90% ethanol water solution in volume concentration, extracting for 1-3 hours each time, filtering, and combining to obtain an extracting solution A;

b) concentrating the extracting solution A at 40-60 ℃ under reduced pressure until the relative density is 1.01-1.07, and drying in vacuum to obtain a gout powder alcohol extract B;

c) dissolving the alcohol extract B with 6-12 times of water, adsorbing by 10-20 times of macroporous resin, sequentially carrying out gradient elution by using ethanol water solutions with different concentrations, collecting ethanol water eluates with the concentration of 50-70%, merging, and carrying out vacuum drying to obtain the gout powder active extract.

3. The method for preparing the active extract of gout decoction powder for resisting hyperuricemia and gout diseases according to claim 2, wherein the extract comprises the following components in percentage by weight: the macroporous resin is selected from one of AB-8, HPD-400, D101, NKA-9 and HPD-826.

4. A pharmaceutical composition characterized by: comprising the extract of claim 1 and a pharmaceutically acceptable excipient.

5. The pharmaceutical composition of claim 4, wherein: the dosage form of the pharmaceutical composition is tablets, capsules, granules, powder, pills, extracts, oral liquid or syrup.

6. The use of the active extract of gout powder of claim 1 in the preparation of anti-hyperuricemia and anti-gout drugs.